Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23355217)

1.

Evaluation of the urinary threshold concentration of formoterol in sports drug testing.

Ventura R, Damasceno LM, Ramírez R, Farré M, Bergés R, Segura J.

Drug Test Anal. 2013 Apr;5(4):266-9. doi: 10.1002/dta.1450. Epub 2013 Jan 25.

PMID:
23355217
2.

Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations.

Eibye K, Elers J, Pedersen L, Henninge J, Hemmersbach P, Dalhoff K, Backer V.

Med Sci Sports Exerc. 2013 Jan;45(1):16-22. doi: 10.1249/MSS.0b013e318269fba2.

PMID:
22843108
3.

Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis.

Deventer K, Pozo OJ, Delbeke FT, Van Eenoo P.

Drug Test Anal. 2012 Jun;4(6):449-54. doi: 10.1002/dta.418. Epub 2012 Mar 22.

PMID:
22447497
4.

Development and validation of a ultra high performance liquid chromatography-tandem mass spectrometric method for the direct detection of formoterol in human urine.

Sardela VF, Deventer K, Pereira HM, de Aquino Neto FR, Van Eenoo P.

J Pharm Biomed Anal. 2012 Nov;70:471-5. doi: 10.1016/j.jpba.2012.06.042. Epub 2012 Jul 7.

PMID:
22841556
5.

Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.

Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della Cioppa G.

Eur J Clin Pharmacol. 1999 Apr;55(2):131-8.

PMID:
10335908
6.

Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.

Ventura R, Segura J, Bergés R, Fitch KD, Morton AR, Berruezo S, Jiménez C.

Ther Drug Monit. 2000 Jun;22(3):277-82.

PMID:
10850394
7.

Impact of ethnicity, gender, and dehydration on the urinary excretion of inhaled salbutamol with respect to doping control.

Dickinson J, Hu J, Chester N, Loosemore M, Whyte G.

Clin J Sport Med. 2014 Nov;24(6):482-9. doi: 10.1097/JSM.0000000000000072.

PMID:
24518370
8.

The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects.

Elers J, Pedersen L, Henninge J, Hemmersbach P, Dalhoff K, Backer V.

Clin J Sport Med. 2012 Mar;22(2):140-5. doi: 10.1097/JSM.0b013e31823513e1.

PMID:
22388343
9.

Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.

Bergés R, Segura J, Ventura R, Fitch KD, Morton AR, Farré M, Mas M, de La Torre X.

Clin Chem. 2000 Sep;46(9):1365-75.

10.

Urine concentrations of oral salbutamol in samples collected after intense exercise in endurance athletes.

Hostrup M, Kalsen A, Auchenberg M, Rzeppa S, Hemmersbach P, Bangsbo J, Backer V.

Drug Test Anal. 2014 Jun;6(6):528-32. doi: 10.1002/dta.1568. Epub 2013 Oct 25.

PMID:
24166762
12.

A simplified procedure for the analysis of formoterol in human urine by liquid chromatography-electrospray tandem mass spectrometry: application to the characterization of the metabolic profile and stability of formoterol in urine.

Mazzarino M, de la Torre X, Fiacco I, Pompei C, Calabrese F, Botrè F.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jul 15;931:75-83. doi: 10.1016/j.jchromb.2013.05.021. Epub 2013 May 28.

PMID:
23777613
13.

Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis.

Deventer K, Pozo OJ, Delbeke FT, Van Eenoo P.

Ther Drug Monit. 2011 Oct;33(5):627-31. doi: 10.1097/FTD.0b013e318229c5f4.

PMID:
21912333
14.

Urine concentrations of repetitive doses of inhaled salbutamol.

Elers J, Pedersen L, Henninge J, Hemmersbach P, Dalhoff K, Backer V.

Int J Sports Med. 2011 Aug;32(8):574-9. doi: 10.1055/s-0031-1273755. Epub 2011 May 11.

PMID:
21563035
15.

Inhaled salbutamol and doping control: effects of dose on urine concentrations.

Sporer BC, Sheel AW, Taunton J, Rupert JL, McKenzie DC.

Clin J Sport Med. 2008 May;18(3):282-5. doi: 10.1097/JSM.0b013e3181705c8c.

PMID:
18469572
16.

Determination of salbutamol and salbutamol glucuronide in human urine by means of liquid chromatography-tandem mass spectrometry.

Mareck U, Guddat S, Schwenke A, Beuck S, Geyer H, Flenker U, Elers J, Backer V, Thevis M, Schänzer W.

Drug Test Anal. 2011 Nov-Dec;3(11-12):820-7. doi: 10.1002/dta.367. Epub 2011 Nov 14.

PMID:
22081503
17.

The effects of inhaled formoterol on the autonomic nervous system in adolescents with asthma.

Sekerel BE, Sahiner UM, Can M, Abali G, Alehan D, Aytemir K.

Ann Allergy Asthma Immunol. 2011 Sep;107(3):266-72. doi: 10.1016/j.anai.2011.06.006. Epub 2011 Jul 20.

PMID:
21875547
18.

Searching for new markers of endogenous steroid administration in athletes: "looking outside the metabolic box".

Cawley AT, Hine ER, Trout GJ, George AV, Kazlauskas R.

Forensic Sci Int. 2004 Jul 16;143(2-3):103-14.

PMID:
15240029
19.

Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.

Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K.

Respir Med. 2013 Feb;107(2):180-95. doi: 10.1016/j.rmed.2012.10.025. Epub 2012 Dec 25.

20.

Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes.

Wolfarth B, Wuestenfeld JC, Kindermann W.

Endocrinol Metab Clin North Am. 2010 Mar;39(1):75-87, ix. doi: 10.1016/j.ecl.2009.10.005.

PMID:
20122451
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk